SAN DIEGO — Getting goose bumps doesn’t just make hairs stand on end; it may also help hair grow.
Nerves and muscles that raise goose bumps also stimulate stem cells in the skin to make hair follicles and grow hair. Ya-Chieh Hsu, a stem cell researcher at Harvard University, reported the unpublished findings December 9 at the joint meeting of the American Society for Cell Biology and the European Molecular Biology Organization. Getting goose bumps when it’s cold may encourage animals’ fur to grow thicker, Hsu said. Nerves that are part of the sympathetic nervous system — which controls pupil dilation, heart rate and other automatic processes — nestle next to stem cells that will create hair follicles, Hsu and her colleagues found. Usually nerves are wrapped in a protective coating called myelin, like electrical wire sheathed in plastic. But Hsu’s group found that the nerves’ ends were naked where they meet hair follicle stem cells, like wires stripped at the tips to make contacts with electrical nodes.
The nerves secrete the hormone norepinephrine. That hormone is necessary for hair growth, the researchers found. Those findings might help explain why hair loss is a side effect of drugs known as beta-blockers, which interfere with norepinephrine’s action.
Sympathetic nerves next to hair follicles are also wrapped around tiny arrector pili muscles, which contract to make hair cells stand on end, causing goose bumps. Mice with mutations that prevented the muscles from growing also lacked the sympathetic nerves and didn’t grow hair normally. Men with male pattern baldness also lack arrector pili muscles in their scalps, Hsu said, suggesting that sympathetic nerves and goose bump–raising muscles may also be important in that type of baldness. Restoring the nerves and muscles may lead to new hair growth, she said.
From tales about whales to enthralling scientific histories and the memoir of a frustrated astrophysicist, 2018 was a banner year for science books. Here are Science News’ picks for the titles that should be on any science lover’s bookshelf. Find detailed reviews of many of these books in the links below and in our Editor’s Pick: Favorite books of 2018.
The Truth About Animals Lucy Cooke
A zoologist debunks myths about bats, pandas, Adélie penguins and many other misunderstood creatures, recounting surprising stories from the animal kingdom (SN: 4/14/18, p. 26). Basic Books, $28
Spying On Whales Nick Pyenson
In this captivating look at whales, a paleontologist dives into the animals’ past, exploring how some of Earth’s most intelligent species came to be, and their uncertain future (SN: 7/7/18, p. 29). Viking, $27
Eager Ben Goldfarb
Some people see beavers as pests. But a science writer explains how the dam-building rodents are actually vital ecosystem engineers that can create or expand habitats that benefit the entire wildlife community (SN: 8/4/18, p. 28). Chelsea Green Publishing, $24.95
The Rise and Fall of the Dinosaurs Steve Brusatte
In this memoir, a paleontologist blends experiences from his career with evolutionary science to take readers on an engrossing journey through time, from the beginnings of the dinosaurs to their ultimate extinction. William Morrow, $29.99
The Big Ones Lucy Jones
A seismologist examines past catastrophic natural disasters, including volcanic eruptions, earthquakes and floods, and their impact on culture, politics and society (SN: 3/31/18, p. 26). With the past as a guide, the author warns readers to be prepared for when the next disaster strikes. Doubleday, $26.95
Losing the Nobel Prize Brian Keating
An astrophysicist’s dream of winning a Nobel Prize turned to dust after a promising experiment failed to find the first definitive evidence of cosmic inflation. The experience revealed how the prize can hamper scientific progress (SN: 4/14/18, p. 27). W.W. Norton & Co., $27.95
The Poisoned City Anna Clark
Weaving together history, science and reporting, a journalist explores the public health crisis that began in Flint, Mich., when lead started leaching into residents’ drinking water (SN: 7/21/18, p. 28). Metropolitan Books, $30
The Poison Squad Deborah Blum
A Pulitzer Prize–winning journalist tells the story of a government chemist at the turn of the 20th century and his mission to make food safe in the United States. Penguin Press, $28
Aroused Randi Hutter Epstein
The history of endocrinology makes for a strange and fascinating read, from the scientists who discovered the effects of hormones to the people whose lives have been irrevocably changed by these powerful substances (SN: 7/7/18, p. 28). W.W. Norton & Co., $26.95
Nine Pints Rose George
Blood, the feared as well as revered substance that flows throughout the human body, has a rich historical and scientific past (SN: 10/27/18, p. 28). Metropolitan Books, $30
She Has Her Mother’s Laugh Carl Zimmer
This comprehensive history recounts how researchers have come to understand genetic inheritance. Looking to the future, the author considers risks of gene manipulation (SN: 6/9/18, p. 29). Dutton, $30
Genetics in the Madhouse Theodore M. Porter
Using archival records, a science historian traces the origins of the study of human heredity to insane asylums in the 1800s (SN: 7/7/18, p. 29). Princeton Univ., $35
The Tangled Tree David Quammen
In chronicling the lives of researchers who made important advances in molecular biology and genetics, this book shows how recent findings shake up our understanding of evolution and the tree of life. Simon & Schuster, $30
SEATTLE — The next generation exoplanet hunter is coming into its own. NASA’s Transiting Exoplanet Survey Satellite, or TESS, has already found eight confirmed planets in its first four months of observing — and some are unlike anything astronomers have seen before.
“The torrent of data is starting to flow already,” TESS principal investigator George Ricker of MIT said January 7 in a news conference at a meeting of the American Astronomical Society.
TESS launched in April and began science observations in July (SN: 5/12/18, p. 7). It was designed to be a follow-up to the prolific Kepler space telescope, which went dark in October after almost a decade of observing (SN Online: 10/30/18). Like Kepler, TESS searches for planets by watching for dips in starlight as planets cross, or transit, in front of their stars. Unlike Kepler, which stared unblinkingly at a single patch of sky for years, TESS scans a new segment of sky every month. Over two years, TESS will cover the entire 360 degrees of sky visible from Earth’s orbit.
In the first four segments, TESS has already spotted eight confirmed planets and more than 320 unconfirmed candidates, said Xu Chelsea Huang of MIT. And several of them are downright strange. Take the third-found planet, HD 21749b. Only 52 light-years away, it has the lowest temperature known for a planet orbiting a bright, nearby star, astronomers reported at the meeting and in a paper posted at arXiv.org on January 1. That makes it a great candidate for follow-up observations with future telescopes like the James Webb Space Telescope, scheduled to launch in 2021. Webb will use starlight filtering through the atmospheres of planets like this one to measure those atmospheres’ properties and search for signs of life (SN: 4/30/16, p. 32).
“If we want to study atmospheres of cool planets, this is the one to start with,” Huang said.
“Cool” is a relative term. This particular planet is still probably too hot and gassy to host life. Its orbit takes 36 Earth days, the longest known orbital period for planets transiting bright stars within 100 light-years of the sun.
That leaves it at a distance from the star that should heat the planet’s surface to about 150° Celsius, too hot for liquid water. And at 2.84 times Earth’s size and 23.2 times Earth’s mass, its density suggests it must have a thick atmosphere, unlike Earth’s life-friendly one.
But it’s still worth checking out, says astronomer Diana Dragomir of MIT, a member of the TESS team. Despite its heat, this planet is “tepid” compared with most of the scorched worlds whose atmospheres astronomers can probe right now, she says, so closer to an Earthlike system. Smaller, cooler, more Earthlike worlds are few and far between, and may not orbit such bright stars.
Finding more longer-period planets “helps you explore the diversity of planets that are out there,” says astronomer Paul Dalba of the University of California, Riverside, who studies exoplanet atmospheres but was not involved in the TESS discovery. Because TESS spends such a short stretch of time looking at each segment of the sky, astronomers expect most of its planets to have shorter years than an Earth month. “The fact that we’re already getting one that’s longer period I think is just really exciting, showing that TESS isn’t just for the shortest-period exoplanets.” The other planets in TESS’s first haul are equally exotic. TESS’s first find, Pi Mensae c, was reported in September ( SN Online: 9/18/18 ). The planet orbits its star every 6.27 days, and is about 2.14 times Earth’s size and 4.8 times Earth’s mass, giving it a density similar to pure water. The weirdest thing about that super-Earth is the company it keeps, Huang said. Previous observations showed that the star Pi Mensae also has a planet 10 times the mass of Jupiter that orbits every 5.7 years. That planet, Pi Mensae b, revolves on a wildly eccentric orbit, swinging between the distance of Earth and the distance of Jupiter from its star.
“This is the most extreme system we know of that has this type of architecture,” Huang said.
Theories of how planets develop such wonky orbits suggest that this super-Jupiter should have booted Pi Mensae c out of the system (SN: 5/12/18, p. 28). “We are really surprised that the inner super-Earth actually survived that disruptive event,” Huang said. “It’s a mystery we really want to understand.”
The second planet found by TESS, LHS 3844b, has a radius just 1.3 times Earth’s. But it swings around its star every 11 hours, giving it a surface temperature of about 540° C, Huang said. “It’s likely a lava world.”
TESS has completed about one-twelfth of its first sky survey, but Ricker is already writing proposals to extend its initial two-year mission. TESS’s orbit is held stable by the moon’s gravity, so it doesn’t need to spend any fuel to stay put. The fuel on board, used to change the direction the telescope points, is enough to last for 300 years.
“The orbit itself was designed to be extremely stable on timescales of decades to centuries,” Ricker said. “TESS is really going to be an important part of our astronomical efforts for the next decade and for more to come.”
Editor’s note: This story was updated January 29, 2019, to correct the description of the planet LHS 3844b’s orbit. It orbits a star, not a planet.
Poop contains a lot of valuable scientific information. Researchers can monitor microbes, track enzyme activity or hunt for DNA to gather clues about overall health.
There’s so much one can learn from the waste product that microbiologist Aadra Bhatt at the University of North Carolina at Chapel Hill decided there should be a word for that research — something in the same vein as “in vivo” (research done in living animals) and “in vitro” (research done in a petri dish).
After some linguistic digging, she and two colleagues settled on “in fimo.” The term comes from fimus, one of several Latin words for manure or excrement. Their choice won out over the more obvious option of “in feces” because the word feces doesn’t have the same rich scatological legacy — originally it referred to the dregs in a wine cask, Bhatt says.
She and her colleagues, while already using in fimo at meetings and seminars, published their argument online December 13 in Gastroenterology. Compared with the laborious process of pulling together a scientific paper, coming up with this term was “delightful — and it wasn’t particularly drawn out,” Bhatt says. She hopes the word catches on and gains a place in the lexicon for poopetuity.
A few months back, a new storefront appeared in my small Oregon town. Its shelves were packed with tinctures, jars of salve, coffee beans, bath bombs — even beard oil. This motley collection shared a single star ingredient: CBD.
Produced by the cannabis plant, CBD is the straitlaced cousin of marijuana’s more famous component — the THC that delivers a mind-swirling high. CBD, or cannabidiol, has no such intoxicating effects on the mind. Yet the molecule has captured people’s attention in a profound way, sold as a remedy for pain, anxiety, insomnia and other ailments — all without the high.
That neighborhood shop, CBD Scientific, is far from alone in its efforts to sell people on the benefits of CBD, which is found in both marijuana and hemp, two versions of the Cannabis sativa plant. CBD is popping up in products in pet stores, coffee shops and the health and beauty sections of mainstream grocery stores. It’s even being brewed into beer. I left the shop with a $5 bottle of water infused with “5,000,000 nanograms” of CBD.
So far, messages of CBD’s purported health benefits come from people trying to sell CBD products — not from scientists, says Margaret Haney, a neurobiologist who directs the Marijuana Research Laboratory at Columbia University. A gaping chasm separates the surging CBD market and the scientific evidence backing it. While there are reasons to be excited about CBD, the science just isn’t there yet, Haney says. Scientists still don’t know all of the targets CBD hits in the human body, nor what effects it may have, if any. With the exception of tests in people with rare forms of epilepsy, large studies that compare CBD with placebos in people are rare. Much of the existing research was done with cells in the lab or in lab animals, with results that don’t necessarily translate to people.
And there’s always the chance that for some people, CBD’s magic is made not by the compound itself but by a powerful placebo effect; people who expect good outcomes are more likely to see benefits.
Researchers are stepping into the void, lured by promising early data. Small trials are under way looking at the effect of CBD on anxiety, pain, opioid addiction, depression and other health problems. National Institutes of Health funding for CBD studies went from zero in 2014 to an estimated $16 million in 2018. “We’re very interested in CBD,” says Susan Weiss, director of the Division of Extramural Research at the National Institute on Drug Abuse in Bethesda, Md. Still, she urges caution to people eager to try CBD. Because of lax oversight, there’s no telling what’s inside many of those tinctures, oils, rubs and foods for sale online and in stores. “A lot of the products that people are taking may not be what they think,” she says.
Despite the risks and warnings, it seems safe to say that the collective fascination with CBD isn’t going to wear off anytime soon. “People think it’s great for everything,” says cognitive neuroscientist Kent Hutchison of the University of Colorado Boulder. That can’t possibly be true, he says. “But I do think it’s going to be great for some things. We just need to figure out what those things are.”
Mystery molecule Each morning, Samantha Montanaro of Portland, Ore., drops a CBD tincture under her tongue. “I’m kind of testing out my own body with this,” she says. “I’m finding that it really helps with anxiety and stress.”
Montanaro isn’t alone; CBD testimonials are increasingly easy to find. In 2016, Montanaro, now 35, cofounded Tokeativity, a global cannabis community for women. Back then, “CBD wasn’t even a thing,” she says. But the first sparks of the CBD movement caught fire fast. “It’s been pretty crazy to watch how things have evolved,” she says. Some bullish analysts predict that the CBD market in the United States will balloon from hundreds of millions of dollars in 2018 to almost $20 billion by 2022.
Ziva Cooper directs UCLA’s Cannabis Research Initiative and fields a lot of questions about CBD. Her answers invariably disappoint. “When I tell [people] we don’t have very much evidence in people, they’re actually surprised,” she says. When it comes to CBD’s benefits, “there’s actually very little out there to hang our hats on.”
The one exception is for rare forms of childhood epilepsy. Neurologist Elizabeth Thiele of Massachusetts General Hospital in Boston had a young patient who was having over 100 seizures a day. After other treatments had failed, the boy’s parents began searching for a source of CBD oil, which they desperately wanted to try after learning about promising early results in animals. The family flew to England, so the boy could try the CBD formulation made by GW Pharmaceuticals. The child’s results, Thiele says, were remarkable. After a week of CBD, his daily seizures had fallen to single digits. That result ultimately led to clinical trials, one of which included 171 people, mostly children, with Lennox-Gastaut syndrome, a rare and severe seizure disorder. In addition to their normal medication, half of the participants got doses of CBD that were rigorously tested and standardized by the drug’s maker. The other half received their regular treatment plus a placebo. After 14 weeks, the people taking CBD saw a median drop in monthly seizure frequency of about 44 percent; seizures in people who took the placebo dropped almost 22 percent. Thiele and her colleagues published those results in March 2018 in the Lancet.
Side effects were manageable, the researchers found. Diarrhea, sleepiness, poor appetite and vomiting were more likely to occur in the people who took CBD than in those who got the placebo. Along with results from several other trials, those data were strong enough to prompt the U.S. Food and Drug Administration to approve the CBD drug, called Epidiolex, last June. Despite rigorous testing of Epidiolex, big gaps in knowledge on how the drug works in epilepsy remain. Researchers don’t know how CBD tames seizures. Because the molecule comes from cannabis, the early assumption was that CBD latches onto the same chemical receptors that THC connects to, one primarily in the brain and one mainly on immune cells. It turns out, however, that CBD doesn’t seem to hit either of those receptors.
Instead, studies in rats and mice point to two different targets. One, called TRPV1, is known to play a role in pain sensation and maybe epilepsy, too. The other, called GPR55, might change the activity level of nerve cells in the brain, a feat that may be behind CBD’s antiseizure power.
Scientists also don’t know whether CBD keeps working year after year. For some of Thiele’s patients, CBD seems to still be effective after five years of taking the drug, even allowing them to taper off some of their other medications, she says. But data from 92 other patients, presented in December at the American Epilepsy Society’s annual meeting, suggest that CBD’s benefits can start to fade after about seven months on the drug. About a third of the people in the study needed a dose increase after their CBD doses became less effective, researchers from Tel Aviv Sourasky Medical Center reported.
Research on CBD and other ailments lags way behind the epilepsy work. Early experiments, mostly on lab animals but some in small numbers of people, suggest that CBD might fight anxiety, ease schizophrenia symptoms and address pain.
One example: Healthy men who took CBD before a stressful public speaking task were calmer than those who took a placebo, researchers reported in October in the Brazilian Journal of Psychiatry. But only the 15 men who received doses of 300 milligrams were more relaxed. The 27 who took less or more CBD didn’t see benefits. Other types of studies with people, and studies of mice and rats, have turned up antianxiety effects, too. But most of these studies looked at single doses of CBD, not consistent use.
Early evidence of CBD’s promise against schizophrenia comes from a trial of 88 people with the disorder. After six weeks, people who had received a big daily dose of CBD (1,000 milligrams a day) in addition to their normal medication had more improvements in certain symptoms when compared with people who received a placebo. Those results hint that CBD might be a new type of drug for schizophrenia, researchers wrote in March 2018 in the American Journal of Psychiatry.
Studies in lab animals suggest that CBD may help relieve chronic pain. A study appearing in 2017 in Pain found that CBD could block osteoarthritis pain and nerve damage in rats. Hard data for humans are harder to find, but anecdotes abound. Pain clinician Kimberly Mauer of Oregon Health & Science University in Portland and colleagues at the OHSU Comprehensive Pain Center have seen an uptick in patients who say they’re taking CBD. Their experiences are mixed, she says: “About half the patients say they get some benefit, and about half say they didn’t notice anything.”
No easy access To answer the many outstanding questions about CBD’s effects, scientists need access to the compound. But a complex web of U.S. regulations makes that difficult. CBD is subject to rules from both the FDA and the U.S. Drug Enforcement Administration. CBD produced by the marijuana plant remains on the DEA’s list of the most restrictive class of drugs, Schedule 1, alongside LSD, ecstasy and other drugs deemed to have no accepted medical use and high potential for abuse. Access restrictions on industrial hemp, and by extension, the CBD that comes from hemp, were eliminated in the 2018 Farm Bill, signed into law in December. However, regardless of its provenance, CBD is still subject to FDA regulations, as well as any regulations imposed by states. “As easy as it’s gotten for the average person to go legally to buy recreational marijuana and consume it in many states, it’s gotten harder for scientists,” says Haney at Columbia. One of the few approved sources of CBD is a government-sanctioned cannabis facility at the University of Mississippi in Oxford. After she gets the CBD she needs for her studies, Haney is required to meticulously account for every milligram. “I have a gun safe in a locked room that I get into with my fingerprints to store both cannabidiol and marijuana.”
With those restrictions, many scientists just can’t do the studies they want, Hutchison says. “The whole thing is a little bit crazy. People can sell it everywhere, but it’s very difficult for scientists to study its effects in humans.”
Hutchison and colleagues have figured out a legal work-around that doesn’t require researchers to obtain supplies of CBD. The team is avoiding the government-grown cannabis, which can be quite different from the products in circulation, by testing the effects of the cannabis products that people are actually using. To do this, the researchers created a mobile pharmacology lab they call the CannaVan. The tricked-out Dodge contains equipment to study people after they’ve taken a product containing CBD (or THC) that they bought themselves. The researchers are currently collecting data on CBD’s effects on anxiety and pain. Buyer beware FDA rules say that CBD cannot be legally added to food and sold across state lines, sold as a dietary supplement or marketed with claims of treating diseases. But aside from sending some warning letters, the FDA has, so far, let the marketplace run uninhibited. (Some local health authorities, however, are beginning to flex their might, warning restaurants in New York City, for instance, to take CBD off the menu.)
Overall, no one really knows what’s inside the bottles, rubs and coffees for sale. A study published in 2017 in JAMA gives a sense of the problem. Researchers ordered and tested 84 products sold online in 2016 as CBD-containing products. Of those, only 26 were labeled accurately (containing CBD within 10 percent of the claimed amount); 36 of the products had more CBD than their labels said; and 22 products had less. The researchers also found THC in 18 of the 84 samples. Sophie Cloyd is a 30-year-old manager for the CBD company Ablis of Bend, Ore. She is also pregnant. I met her recently at a ski lodge, where she was offering beverage tastes and describing tinctures, oils and lotions. CBD, she says, has helped her manage this pregnancy, her second. She was prescribed the anti-nausea drug Zofran early in her pregnancy, but “the research on Zofran scared me more than the lack of research on CBD,” she says.
Ablis, which makes CBD-infused fizzy drinks and other products, currently gets purified CBD from Colorado, Cloyd says. When the CBD arrives, the company sends it to an independent lab to confirm that it has the right amount of CBD, no pesticides and no THC. But not all CBD sellers test their products.
An unexpected THC dose might not be enough to get a user high, but it could still be a problem, as news reports have begun to point out. To ease his pain from psoriatic arthritis, a school bus driver in Beaverton, Ore., had been taking a daily dose of CBD oil. In early 2018, he failed a periodic drug test with high THC levels, which caused him to lose his job, Portland news channel KATU reported. Even seemingly small amounts of THC can build up in the body with repeated use.
A product might contain even worse surprises. Between December 2017 and January 2018, for example, 52 people fell ill in Utah, with symptoms such as hallucinations, vomiting and seizures, after taking what they thought was CBD. It turned out that the products, many labeled “Yolo CBD oil,” contained a synthetic cannabinoid, and it had poisoned them.
Even if product labels were always accurate, people have no idea of the correct dose of CBD (assuming the right dose would be effective). “You see it marketed in doses like 10 milligrams,” Hutchison says. “Well, 10 milligrams probably does nothing.” For comparison, people who participated in one Epidiolex study took 20 milligrams per kilogram of body weight. To reach that daily dose, I’d need to chug 254 bottles of that 5 million nanogram CBD water I bought — at a cost of $1,270.
Haney makes the same point: “You’re not getting anything resembling an effective dose when you get CBD added to your coffee, or you buy a mint with a little bit of CBD in it,” she says.
There’s even less known about CBD products that you rub on your skin. Scientists don’t know that CBD in creams, oils and ointments actually makes it into the body. “I’m not convinced that anything you’re rubbing on your body with CBD is even getting through,” Haney says. At its heart, the trouble is that most CBD use isn’t backed up by science, Haney says. “I am not against CBD,” she says. In fact, she is about to start a study looking at CBD to treat nerve pain due to chemotherapy in cancer patients. “But I don’t like marketers determining what it’s good for and what it’s not.”
Hype run amok isn’t anything new, says Mauer, the OHSU pain doctor. Consumers try lots of things before the science is definitive — keto diets, for instance, or vitamin D supplements (SN: 2/2/19, p. 16). And even if it turns out that the chemical doesn’t work, the placebo effect might be enough to help reduce symptoms.
So far, the science on CBD isn’t mature enough to weigh in, one way or another. But judging by the number of studies and clinical trials under way, this nascent research field is growing up fast, seeking to quickly fill the space between the science and what people want to know.
This research boom heartens Montanaro. Her message to the scientific community: “I would encourage curiosity,” she says. “I’m not a doctor, and I’m not a scientist, but I certainly know my own body,” and she says that CBD helps her. From her perspective, science has got some catching up to do.
This story appears in the March 30, 2019 issue of Science News with the headline, “The Allure of CBD: People seek health benefits despite lack of evidence.”
Robot revolution? Educational robots could help students learn new skills and good study habits. But researchers still have a lot to learn about the potential risks involved when young kids keep close company with such robots, Maria Temming reported in “Robots are becoming classroom tutors. But will they make the grade?” (SN: 2/16/19, p. 16).The story reminded reader A. Bogart of Isaac Asimov’s novel The Naked Sun, in which robots and humans live side by side. Asimov “raised the specter of some of the same issues with which scientists are now grappling,” Bogart wrote. Although Asimov had a positive view of science and innovation, all inventions are force multipliers, Bogart noted. “That means they can be used to multiply the effects of good and evil,” Bogart wrote. “Even at this early stage, it is well to think about negative impacts as well as positive ones.” Dogged questions Bone fragments of dogs and other animals unearthed from Shubayqa 6, the site of an ancient settlement in Jordan, suggest that dogs may have helped humans devise new ways of hunting small game around 11,500 years ago, Bruce Bower reported in “Dogs may have helped ancient Middle Easterners hunt small game” (SN: 2/16/19, p. 13).
Reader Eric Hobday took issue with the researchers’ conclusion that dogs assisted with hunting. “I will accept as fact that the bones in Shubayqa show signs of having passed through a dog’s digestive system. However, this in no way indicates that the dog in Shubayqa was any more involved in hunting the animal than my dog was,” Hobday wrote. He suggested that the dogs could have been feral and scavenged villagers’ leftovers. “No evidence of domestication was presented, yet the article says the findings offer new insights into domestication,” Hobday wrote. “Really?”
By comparing bones of modern Afghan hounds, greyhounds, gray wolves and golden jackals, researchers have determined that the Shubayqa 6 bones likely came from domesticated dogs, Bower says. “As pointed out in the story, the presence of numerous dogs at the site fits with observations of modern foragers who use dogs to locate small prey during hunts,” he says. “Reconstructions of ancient behavior are always provisional.” Soil science High demand for sparkling wine may be depleting 400 million kilograms of soil every year from northeastern Italy’s vineyards, Cassie Martin reported in “Prosecco production takes a toll on northeast Italy’s environment” (SN: 2/16/19, p. 5).
“The best wine grows in poor soil conditions,” reader Jonathan Quint wrote. “Is erosion even a concern for a vineyard?”
Soil erosion isn’t necessarily a bad thing. It can help generate new soils to keep an ecosystem healthy. But such a high rate of soil erosion in Italy is a big concern, says Jesús Rodrigo Comino, a geographer at the University of Málaga’s Institute of Geomorphology and Soils in Spain. The current rate is unsustainable and could actually harm vineyards there. A few simple changes, like leaving grass between rows of vines as well as planting hedges around vineyards and vegetation along rivers and streams, might help prosecco vineyards reduce their soil loss, scientists suggest.
On the rise Deaths involving a type of antianxiety medication rose 830 percent from 1999 to 2017 in U.S. women ages 30 to 64, Aimee Cunningham reported in “Overdose deaths tied to antianxiety drugs like Xanax continue to rise” (SN: 2/16/19, p. 12).
Reader Dan Furtado asked if benzodiazepines alone cause overdose deaths. He thought that the drugs, such as Xanax and Valium, could cause an overdose only if a person had additional medical issues or combined the drugs with opioids or similar substances.
“An overdose of benzodiazepines alone can cause death,” Cunningham says. “The drugs depress the central nervous system, so a person who overdoses can stop breathing. But overdose deaths are more likely to happen when benzodiazepines are taken with opioids or alcohol,” she says.
For 40 years, they’ve held the front line in Florida’s fight against mosquito-borne diseases. And it turns out that the chickens standing sentinel in cities, marshes, woodlands and residential backyards are clucking good at their job.
Last year, chickens in 268 coops in over a third of Florida’s counties provided scientists weekly blood samples that revealed whether the birds had been bitten by mosquitoes carrying West Nile virus or the Eastern equine encephalitis or St. Louis encephalitis viruses. If a chicken’s blood tests positive for antibodies to one of those viruses, authorities know that the pathogen is circulating. And if enough birds have the antibodies, state officials can ratchet up mosquito-killing measures such as pesticide spraying to help halt disease spread.
The sentinel chicken surveillance programs are “a really good way of monitoring” for certain virus activity, says Thomas Unnasch, a biologist who studies vector-borne diseases at the University of South Florida in Tampa. The birds “are sampling literally hundreds or thousands of mosquitoes every day,” he says. (The chickens can’t keep tabs on dengue or Zika; the mosquitoes carrying those viruses prefer to bite people rather than birds.) In 2018, 833 chickens tested positive for West Nile virus antibodies in Florida, but only 39 people did, according to data from the state’s health department. For Eastern equine encephalitis virus, 154 chickens tested positive in 2018, compared with only three people. Chickens that test positive for the viruses being surveyed don’t transmit them, and people don’t either. Both are considered “dead-end hosts,” meaning that the viral concentration in the blood doesn’t get high enough to infect another mosquito after it bites. Infected cardinals, robins and other backyard birds are the animal reservoirs that help keep the three viruses spreading in the area. Sentinel chickens, by detecting where and when disease-carrying mosquitoes are buzzing, are also providing valuable data on how a virus can spread. Data from 2005 to 2016 revealed that Eastern equine encephalitis virus is active year-round in the Florida panhandle, making the area a source from which the virus moves elsewhere in the state and along the eastern United States, Unnasch and his colleagues report online March 11 in the American Journal of Tropical Medicine and Hygiene.
In people, the viral diseases monitored by the chickens are relatively rare, but can be deadly. The chickens don’t get especially sick, though. “You don’t usually see any symptoms at all,” Unnasch says.
Any chicken whose blood tests positive for the antibodies is removed from the coops since that bird can no longer alert authorities to a new infection. For these chickens, retirement may be spent on a farm, with school or 4-H clubs, or in a backyard coop, depending on the county. The sentinel chicken programs are ready with replacements, raising chicks to supply new birds to signal “where we have a threat to human health,” Unnasch says.
A world-spanning network of telescopes called the Event Horizon Telescope zoomed in on the supermassive monster in the galaxy M87 to create this first-ever picture of a black hole.
“We have seen what we thought was unseeable. We have seen and taken a picture of a black hole,” Sheperd Doeleman, EHT Director and astrophysicist at the Harvard-Smithsonian Center for Astrophysics in Cambridge, Mass., said April 10 in Washington, D.C., at one of seven concurrent news conferences. The results were also published in six papers in the Astrophysical Journal Letters.
“We’ve been studying black holes so long, sometimes it’s easy to forget that none of us have actually seen one,” France Córdova, director of the National Science Foundation, said in the Washington, D.C., news conference. Seeing one “is a Herculean task,” she said. That’s because black holes are notoriously hard to see. Their gravity is so extreme that nothing, not even light, can escape across the boundary at a black hole’s edge, known as the event horizon. But some black holes, especially supermassive ones dwelling in galaxies’ centers, stand out by voraciously accreting bright disks of gas and other material. The EHT image reveals the shadow of M87’s black hole on its accretion disk. Appearing as a fuzzy, asymmetrical ring, it unveils for the first time a dark abyss of one of the universe’s most mysterious objects.
“It’s been such a buildup,” Doeleman said. “It was just astonishment and wonder… to know that you’ve uncovered a part of the universe that was off limits to us.”
The much-anticipated big reveal of the image “lives up to the hype, that’s for sure,” says Yale University astrophysicist Priyamvada Natarajan, who is not on the EHT team. “It really brings home how fortunate we are as a species at this particular time, with the capacity of the human mind to comprehend the universe, to have built all the science and technology to make it happen.” (SN Online: 4/10/19)
The image aligns with expectations of what a black hole should look like based on Einstein’s general theory of relativity, which predicts how spacetime is warped by the extreme mass of a black hole. The picture is “one more strong piece of evidence supporting the existence of black holes. And that, of course, helps verify general relativity,” says physicist Clifford Will of the University of Florida in Gainesville who is not on the EHT team. “Being able to actually see this shadow and to detect it is a tremendous first step.”
Earlier studies have tested general relativity by looking at the motions of stars (SN: 8/18/18, p. 12) or gas clouds (SN: 11/24/18, p. 16) near a black hole, but never at its edge. “It’s as good as it gets,” Will says. Tiptoe any closer and you’d be inside the black hole — unable to report back on the results of any experiments. “Black hole environments are a likely place where general relativity would break down,” says EHT team member Feryal Özel, an astrophysicist at the University of Arizona in Tucson. So testing general relativity in such extreme conditions could reveal deviations from Einstein’s predictions.
Just because this first image upholds general relativity “doesn’t mean general relativity is completely fine,” she says. Many physicists think that general relativity won’t be the last word on gravity because it’s incompatible with another essential physics theory, quantum mechanics, which describes physics on very small scales. The image also provides a new measurement of the black hole’s size and heft. “Our mass determination by just directly looking at the shadow has helped resolve a longstanding controversy,” Sera Markoff, a theoretical astrophysicist at the University of Amsterdam, said in the Washington, D.C., news conference. Estimates made using different techniques have ranged between 3.5 billion and 7.22 billion times the mass of the sun. But the new EHT measurements show that its mass is about 6.5 billion solar masses.
The team has also determined the behemoth’s size — its diameter stretches 38 billion kilometers — and that the black hole spins clockwise. “M87 is a monster even by supermassive black hole standards,” Markoff said.
EHT trained its sights on both M87’s black hole and Sagittarius A, the supermassive black hole at the center of the Milky Way. But, it turns out, it was easier to image M87’s monster. That black hole is 55 million light-years from Earth in the constellation Virgo, about 2,000 times as far as Sgr A. But it’s also about 1,000 times as massive as the Milky Way’s giant, which weighs the equivalent of roughly 4 million suns. That extra heft nearly balances out M87’s distance. “The size in the sky is pretty darn similar,” says EHT team member Feryal Özel. Due to its gravitational oomph, gases swirling around M87’s black hole move and vary in brightness more slowly than they do around the Milky Way’s. “During a single observation, Sgr A* doesn’t sit still, whereas M87 does,” says Özel, an astrophysicist at the University of Arizona in Tucson. “Just based on this ‘Does the black hole sit still and pose for me?’ point of view, we knew M87 would cooperate more.”
After more data analysis, the team hopes to solve some long-standing mysteries about black holes, such as how M87’s behemoth spews a bright jet of charged particles thousands of light-years into space.
This first image is like the “shot heard round the world” that kicked off the American Revolutionary War, says Harvard University astrophysicist Avi Loeb who isn’t on the EHT team. “It’s very significant; it gives a glimpse of what the future might hold, but it doesn’t give us all the information that we want.” Hopes are still high for a much-anticipated glimpse of Sgr A*. The EHT team was able to collect some data on the Milky Way’s behemoth and are continuing to analyze that data, in the hopes of adding its image to the new black hole portrait gallery.
Since the appearance of that black hole changes so quickly, the team is having to develop new techniques to analyze the data. “We’re very excited to work on Sgr A*,” Daniel Marrone, an astrophysicist at the University of Arizona in Tucson, said in the Washington, D.C., news conference. “We’re doing that shortly. We’re not promising anything but we hope to get that very soon.”
Studying such different environments could reveal more details of how black holes behave, Loeb says. “The Milky Way is a very different galaxy from M87.” The next look at the M87 and Milky Way behemoths will have to wait.
Scientists got a lucky stretch of good weather at all eight sites that made up the Event Horizon Telescope in 2017. Then bad weather in 2018 and technical difficulties, which cancelled the 2019 observing run, stymied the team.
The good news is that by 2020, there will be more observatories to work with. The Greenland Telescope joined the consortium in 2018, and the Kitt Peak National Observatory outside Tucson, Ariz., and the NOrthern Extended Millimeter Array (NOEMA) in the French Alps will join EHT in 2020.
Adding more telescopes could allow the team to extend the image, to better capture the jets that spew from the black hole. The researchers also plan to make observations using light of slightly higher frequency, which can further sharpen the image. And even bigger plans are on the horizon: “World domination is not enough for us; we also want to go to space,” Doeleman said.
These extra eyes may be just what’s needed to bring black holes into even greater focus.
WASHINGTON — In 2021, wildfires pillaged the world’s carbon-rich snow forests.
That year, burning boreal forests released 1.76 billion metric tons of carbon dioxide, researchers reported March 2 in a news conference at the annual meeting of the American Association for the Advancement of Science.
That’s a new record for the region, which stores about one-third of the world’s land-based carbon. “It’s also roughly double the emissions in that year from aviation,” said earth system scientist Steven Davis of the University of California, Irvine. The trend, if it continues, threatens to make fighting climate change even more difficult. Boreal forests are part of the taiga, a vast region that necklaces the Earth just south of the Arctic Circle. Blazes in tropical forests like the Amazon tend to garner more attention for their potential to contribute large amounts of climate-warming gases to the atmosphere (SN: 9/28/17). But scientists estimate that on a per area basis, boreal forests store about twice as much carbon in their trees and soils as tropical forests.
Climate change is causing the taiga to warm about twice as fast as the global average. And wildfires are growing more widespread in the region, releasing more of the trapped carbon, which in turn can worsen climate change (SN: 5/19/21).
Davis and his colleagues analyzed satellite data on carbon emissions from boreal regions from 2000 to 2021. In 2021, emissions from boreal wildfires made up a whopping 23 percent of all the CO2 emitted by wildfires around the world, the researchers report in the March 3 Science. In contrast, CO2 emissions during an average year from 2000 to 2021 were about 10 percent.
The record-breaking emissions coincided with widespread heat waves and droughts in Siberia and northern Canada, probably fueled by human-caused climate change.
There’s no data yet to show if 2022 saw a similar surge in emissions. But, Davis said, “there’s not actually that much evidence that this record will stand for long.”
Full-grown snapping shrimp were already known to have some of the fastest claws under the waves. But it turns out they’re nothing compared with their kids.
Juvenile snapping shrimp produce the highest known underwater accelerations of any reusable body part, researchers report February 28 in the Journal of Experimental Biology. While the claws’ top speed isn’t terribly impressive, they go from zero to full throttle in record time.
To deter predators or competitors, snapping shrimp create shock waves with their powerful claws. The shrimp store energy in the flexing exoskeleton of their claw as it opens, latching it in place much like a bow-and-arrow mechanism, says Jacob Harrison, a biologist at Georgia Tech in Atlanta. Firing the claw and releasing this elastic energy produces a speeding jet of water. Bubbles form behind it and promptly implode, liberating a huge amount of energy, momentarily flashing as hot as the sun and creating a deafening crack (SN: 10/3/01).
But it was unclear how early in their lives the shrimp could use this weaponry. “We knew that the snapping shrimp did this really impressive behavior,” Harrison says. “But we really didn’t know anything about how this mechanism developed.”
While a grad student at Duke University, Harrison and his adviser, biomechanist Sheila Patek, reared bigclaw snapping shrimp (Alpheus heterochaelis) from eggs in the laboratory. At 1 month old, the tiny shrimp — less than a centimeter long — began firing their claws when disturbed. The researchers took high-speed video footage of these snaps and calculated their speed.
The wee shrimp could create the collapsing bubbles just like adults. Despite being a tenth the adults’ size or smaller, the juveniles’ claws accelerated 20 times as fast when firing. This acceleration — about 600 kilometers per second per second — is on “the same order of magnitude as a 9-millimeter bullet leaving a gun,” Harrison says. Dracula ants (Mystrium camillae) and some termites produce more explosive bites but aren’t pushing against water. The stinging cells of jellyfish launch their venomous harpoons about 100 times as fast, but their firing mechanism is inherently single use. Snapping shrimp, on the other hand, can fire their claws again and again. The juveniles’ firing and bubble creation weren’t very reliable at the smallest sizes, but the shrimp routinely tried snapping anyway. The team wonders if the young shrimp could be practicing and training the necessary musculature.
If so, that training might ultimately be crucial to the claw’s function, says Kate Feller, a visual ecologist at Union College in Schenectady, N.Y., who studies similarly ultrafast mantis shrimp and was not involved in the new study. “If you were to somehow manipulate the claws so that they couldn’t properly close and they couldn’t snap,” she wonders, “would that affect their ability to develop these mechanisms?”
Understanding the storage of elastic energy in biological materials and how it flows through them is “tricky,” Harrison says. Figuring out how such tiny claws store so much energy without fracturing may help researchers illuminate this superpower.
